On April 1, 2019 Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, reported that its CEO, Dr. David Giljohann, will give a company presentation on Monday, April 8, 2019 at 11:50 am GMT at the H.C. Wainwright Global Life Sciences Conference (Press release, Exicure, APR 1, 2019, View Source;p=RssLanding&cat=news&id=2392908 [SID1234534807]). The presentation will be made in the Stratton Suite of the Grosvenor House in London.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the Investors section of Exicure’s website: www.exicuretx.com. The webcast will be archived for approximately 30 days following the event.

On April 1, 2019 Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, reported that Triphase Accelerator’s TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma, has been dosed in the first patient in a Phase 1 clinical trial (Press release, Catalent, APR 1, 2019, https://www.catalent.com/index.php/news-events/news/Triphase-Accelerator-Initiates-Phase-1-Clinical-Trial-of-TRPH-222-in-B-cell-Lymphoma-Next-Generation-Antibody-Drug-Conjugate-Developed-Using-Catalent-s-SMARTag-R-ADC-Technology [SID1234534806]). TRPH-222 was originally developed by Catalent’s subsidiary Redwood Bioscience, Inc. using the proprietary SMARTag platform, which provides optimized site-specific protein-modification and linker technologies. Triphase Accelerator obtained the worldwide rights to further develop this program and subsequently announced that Celgene had obtained the option to acquire all rights to the program as part of an expanded strategic collaboration.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1 clinical trial is a multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell non-Hodgkin lymphoma (NHL), which will be conducted in two stages, dose-escalation and dose-expansion. The study is currently enrolling patients at sites in the U.S. and Canada, including Roswell Park Cancer Center, University of Pennsylvania, Ohio State University, Sarah Cannon Research Institute, Princess Margaret Cancer Centre and Jewish General Hospital. Additional sites are planned to support the dose-expansion stage. More information about this study can be found at www.clinicaltrials.gov, Identifier NCT03682796.

"We are thrilled to advance the first SMARTag ADC into human clinical trials and evaluate its potential for better tolerability and an expanded therapeutic index as compared to conventional ADCs" said Dr. Mathias Schmidt, Executive Vice President and Head of Research & Development of Triphase Accelerator. "We look forward to assessing the potential clinical benefit of TRPH-222 in patients with relapsed/refractory B-cell lymphoma and remain convinced that this molecule can play an important role in the future treatment of lymphoma."

"We are excited to see Triphase Accelerator reach this important milestone with TRPH-222," added Mike Riley, Vice President and General Manager, Catalent Biologics. "The SMARTag technology has the potential to create ADCs with significantly higher tolerability and expanded therapeutic index. The improved conjugate stability and biophysical characteristics of TRPH-222 has translated to improved tolerability in preclinical testing, and we look forward to further validation in the clinic."

On April 1, 2019 F1 Oncology, an American relations company of Essex Biotech, reported that it will host the 2019 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) in Atlanta from March 29th to April 3rd, 2019 (Press release, Essex Bio, APR 1, 2019, View Source [SID1234534790]). Published four abstracts to support its innovative CAR-T technology for the treatment of malignant solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

F1 Oncology is developing these new CAB-CAR-T therapies for solid tumors that reduce the potential for on-target/off-Tumor toxicity. These four abstracts reveal in depth that F1 uses its proprietary CAB-CAR-T technology to turn the negative effects of the tumor microenvironment (TME) into beneficial signals and enhance the safety of CAR-T treatment. F1 will highlight its proof-of-concept studies of bedside CAR-T treatments on the same day, as well as bioinformatics-driven methods to discover protein domain combinations that can selectively amplify CAR-T cells.

Dr. Gregory Frost, Chairman and CEO of F1 Oncology, said: "The information presented at the conference highlights the scientific advancement that F1 can significantly simplify the future CAR-T treatment of solid tumor malignancies. The company team is in the entity of CAB-CAR-T Significant progress has been made in understanding the role of neonatal cell therapy, and we look forward to the progress of these CAB-CAR-T programs in ongoing clinical research in the Shanghai partner unit."

The abstract can be obtained from the Program Section of the 2019 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Conference. The poster details are as follows:

• Chimeric antigen receptor (CAR) and adoptive cell therapy for the transduction and in vivo expansion of the driving member

The study examined the relationship between in vitro expansion time and poorly differentiated, potently enhanced CAR-T products, as well as the development of bedside treatments for adoptive cell therapy, reducing the potential for CAR-T cell immunotherapy complexity.

Poster number: PO.IM02.03 2327/26

Poster display date and time: April 1, 2019, 1:00 – 5:00 pm.

Venue: Georgia World Congress Center, Poster 22 Division

• A high-throughput screening strategy for identifying novel lymphocyte proliferation elements

A high-throughput screening method for the well-designed high-variation protein subdomain recombination libraries encoded by barcodes was developed to identify new combinations that selectively drive the expansion of CAR-T cells in vivo.

Poster number: PO.MCB09.05 3523/9

Poster display date and time: April 2, 2019, 8:00 am – 12:00 noon

Venue: Overseas Chinese Conference Center, Poster 22 Division

• CAB-CAR-T: a novel conditional initiation of adoptive immunotherapy that reduces potential "on-target/off-Tumor" toxicity

Adoptive immunotherapy for a novel conditional initiation (CAB) approach

Poster number: PO.IM02.04 3189/12

Poster display date and time: April 2, 2019, 8:00 am – 12:00 noon

Venue: Georgia World Congress Center, Poster 22 Division

• CAB-CAR-T: The superiority of conditional initiation biomolecules targeting cell surface proteins for the treatment of various solid tumors

Determine the best target from the cancer genome map. When using CAB-CAR-T, the most applicable population for various cancers

Poster number: PO.BSB01.05 5101/9

Poster display date and time: April 3, 2019, 8:00 am – 12:00 noon

Venue: Georgia World Congress Center, Poster 30